Paul S. Donnelly

This paper develops a patient-derived BBB model to screen copper bis(thiosemicarbazone) complexes for Alzheimer's disease treatment, identifying CuII(dtsm) as a promising candidate with improved BBB permeability and anti-inflammatory effects.

The paper investigates copper availability in sporadic ALS and suggests CuII(atsm) may be therapeutically relevant by improving copper bioavailability.

This study shows that microglial ferroptotic stress leads to non-cell autonomous neuronal death in ALS, with a novel inhibitor reducing neurotoxicity.